| Document |
Document Title |
|
WO/2022/160928A1 |
The present application belongs to the technical field of organic materials. Provided are a nitrogen-containing compound, and an electronic component and an electronic device containing same. The structural formula of the nitrogen-contai...
|
|
WO/2022/161469A1 |
The present invention relates to an intermediate for a thiohydantoin drug, and a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by a formula (I) and multiple preparation methods ther...
|
|
WO/2022/162210A1 |
The present invention covers compounds of general formula (I): [(C)n-L]-(V)m (I) where C is a chelator and n > 1, L is a multi-functional linker moiety comprising multiple functional groups for the covalent attachment of chelator such as...
|
|
WO/2022/164019A1 |
The present invention relates to a reduction-reactive nitric oxide donor compound or prodrug capable of selectively releasing a nitric oxide under in vivo reducing conditions, and can be effectively used for preventing or treating cancer...
|
|
WO/2022/165076A1 |
Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
|
|
WO/2022/160138A1 |
The present invention relates to a benzoxazine-4-one compound represented by formula (I) that acts as a glycogen phosphorylase inhibitor, a preparation method therefor, and a use thereof in a drug for the treatment and/or prevention of d...
|
|
WO/2022/161462A1 |
A substituted morpholine derivative with a structure as shown in a formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use of the derivative.
|
|
WO/2022/156788A1 |
Provided are a new compound for effectively inhibiting the activity of IRAK4, a preparation method therefor, and the use thereof in the preparation of a drug, wherein the new compound is a compound as represented by formula I, and a taut...
|
|
WO/2022/156737A1 |
Disclosed are a crystal form of a compound (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridin-4-yl) benzo [d] oxazol-5-yl) cyclopropyl-1-carboxamide having a structure of formula (...
|
|
WO/2022/156708A1 |
Provided are a PARP7 enzyme inhibitor, a composition containing the inhibitor and the use thereof, synthetic methods for the preparation of PARP7 enzyme inhibitor and useful intermediates thereof.
|
|
WO/2022/152821A1 |
Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula (I). These compounds find use as modulators of cereblon, in particular in the treatment of abnormal cell growth in mammals, especially...
|
|
WO/2022/152852A1 |
This application relates to compounds of Formula (I), which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticar...
|
|
WO/2022/152853A1 |
This application relates to compounds of Formula I which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticaria,...
|
|
WO/2022/150574A1 |
Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
|
|
WO/2022/147872A1 |
The present invention relates to a series of amide derivative neutral mitochondrial fluorescent markers, a preparation method therefor, and an application thereof; the present invention discloses for the first time that, after being link...
|
|
WO/2022/148197A1 |
The present application relates to an organic compound, and an electronic element and electronic device using same. The organic compound has a structure as shown in Formula 1, in which A1 and A2 are independently selected from structures...
|
|
WO/2022/150381A1 |
The present invention relates to novel substituted bicyclic derivatives that can inhibit Rho-kinases and/or Rho-kinase mediated phosphorylation of myosin light chain phosphates, compositions comprising the derivatives, methods for prepar...
|
|
WO/2022/149925A1 |
The present invention relates to a novel oxadiazole phenylalanine derivative and a medical use thereof. A novel tryptophan hydroxylase inhibitor and a pharmaceutical composition, which contain same, inhibit the synthesis of serotonin in ...
|
|
WO/2022/148196A1 |
A multikinase inhibitor and use thereof, a compound of formula I, and an isotope form, a stereoisomer form, a tautomer form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a hydrate, a prodrug, and a polymorph...
|
|
WO/2022/145408A1 |
The present invention provides compounds that have a serotonin 5-HT2A receptor antagonist and/or inverse agonist activity, and pharmaceutically acceptable salts thereof, and also provides a serotonin 5-HT2A receptor antagonist and/or inv...
|
|
WO/2022/147210A1 |
Novel thiazole- and/or isoquinoline- containing compounds are presented that are useful for treating cancers as well as treating and/or preventing viral infections. Methods of treating and/or preventing broad-spectrum viral infections ar...
|
|
WO/2022/147302A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/143773A1 |
Provided are a class of benzimidazole compounds and an application thereof as a 300/CBP inhibitor. Specifically, provided are a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/135572A1 |
A compound represented by general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparation method ther...
|
|
WO/2022/135514A1 |
Provided are a class of multi-substituted uracil derivatives and a pharmaceutical composition containing such compounds, which compounds can be used as chymase inhibitors. Also provided are a method for preparing such compounds and the p...
|
|
WO/2022/136366A1 |
The present invention relates to a novel method for producing NCA compounds. The invention also relates to a novel use of a peptide coupling agent. The method according to the invention enables NCA compounds to be obtained from α-amino ...
|
|
WO/2022/135502A1 |
Provided are a multi-substituted uracil derivative represented by formula (I) and the use thereof. Specifically, the present invention relates to a class of novel multi-substituted uracil derivatives and a pharmaceutical composition cont...
|
|
WO/2022/140326A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2022/140325A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2022/140456A1 |
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I, or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture o...
|
|
WO/2022/133529A1 |
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and ...
|
|
WO/2022/137085A1 |
The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using th...
|
|
WO/2022/138781A1 |
The present invention provides an industrially desirable production method for a sulfone derivative that is useful as a herbicide, and an intermediate thereof.
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/138017A1 |
Damage caused by diseases is still significant in crop production such as in agriculture and horticulture. Thus, there has been a demand for the development of a novel agricultural/horticultural microbicide since there have been outbreak...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/135601A1 |
The present invention provides a 5-alkyl-2-pyrazole-oxazolidine-4-ketone derivative shown in formula (a), and specifically relates to a free base, isomer, solvate, pharmaceutically acceptable salt, and other structural forms of the compo...
|
|
WO/2022/134641A1 |
An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any on...
|
|
WO/2022/134146A1 |
The present invention relates to a novel FXR agonist having a pyrazine structure, a preparation method therefor and the use thereof, and in particular relates to a compound as represented by the following general formula (I), or a hydrat...
|
|
WO/2022/135442A1 |
The present invention provides a CDK2 inhibitor and a preparation method therefor. Specifically, the present invention provides a compound as represented by formula I or a pharmaceutically acceptable salt and tautomer thereof. Groups are...
|
|
WO/2022/134773A1 |
A macrocyclic K-RAS G12C inhibitor, a preparation method therefor and use thereof. The inhibitor can be widely used in preparation of a drug for treating cancer or tumor which is at least partially mediated by a K-RAS G12C mutation, part...
|
|
WO/2022/137370A1 |
The present invention provides an industrially desirable production method for a sulfone derivative that is useful as a herbicide, and an intermediate thereof.
|
|
WO/2022/140547A2 |
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-func...
|
|
WO/2022/138888A1 |
The purpose of the present invention is to provide a compound having a tetrahydroquinoline skeleton, said compound having ferroptosis inhibitory action and exhibiting a treatment effect or a prevention effect for a disease, disorder, or ...
|
|
WO/2022/135534A1 |
A novel substituted nitrogen-containing bicyclic compound and a pharmaceutical composition containing the compound, capable of being used as chymase inhibitors. Also provided are methods for preparing the compound and pharmaceutical comp...
|
|
WO/2022/140290A1 |
Provided herein are compounds of formula (A): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, Ry, and Rz are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2022/127564A1 |
The present invention relates to the technical field of herbicides, and specifically to isoxazoline-containing pyridine biphenyl compounds, a preparation method therefor and the use thereof. The present invention specifically provides co...
|
|
WO/2022/129327A1 |
The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in ...
|
|
WO/2022/127518A1 |
Disclosed by the present application are a nitrogen-containing organic compound and an electronic component and electronic apparatus using same; the nitrogen-containing organic compound has an adamantyl-substituted nitrogen-containing he...
|
|
WO/2022/130304A1 |
The present invention relates to compound of formula (I) fumarate and its crystalline form and methods of their preparation. (I) The invention also relates to preparations suitable for pharmaceutical uses for treatment of various disease...
|
